HBV-Transgenic Hepatocellular Carcinoma Model Service

The HBV-Transgenic Hepatocellular Carcinoma Model Service provides a germline-stable in vivo system in which defined hepatitis B viral genes — most notably the large envelope protein and the HBx transactivator — are expressed in the mouse liver, driving hepatocellular injury, compensatory regeneration, and ultimately hepatocellular carcinoma through mechanisms that mirror virus-linked human liver cancer. Alfa Cytology maintains and applies these transgenic platforms with controlled breeding, genotype verification, scheduled serological and imaging surveillance, and comprehensive terminal pathology — giving sponsors a dependable, well-characterized setting in which to test hypotheses and candidate agents against HBV-associated hepatocarcinogenesis.

Overview of HBV-Transgenic Hepatocellular Carcinoma Model

Chronic hepatitis B virus infection elevates lifetime hepatocellular carcinoma risk roughly one-hundred-fold and accounts for more than half of HCC cases worldwide, yet the virus cannot productively infect murine hepatocytes. The HBV-transgenic solution, introduced in the mid-1980s, circumvents this host barrier by integrating HBV DNA directly into the mouse germline through pronuclear microinjection: full viral genomes or individual viral genes are placed under liver-specific or endogenous HBV regulatory control, so viral proteins are produced in hepatocytes from birth in a state of immunological tolerance. Among the many lines generated, only sustained expression of a limited set of oncogenic products — the large envelope protein, certain pre-S mutants, and the HBx protein — reproducibly culminates in liver cancer, making these lines precise instruments for dissecting viral oncogenesis.

Fig 1. Serum HBsAg, HBeAg, HBV DNA kinetics and liver HBsAg immunohistochemistry of the hydrodynamic injection-induced persistent HBV model in BPS versus control mice over 12–33 weeks post-injection. (Shen, Zhongliang, et al., 2017)

The two canonical routes to malignancy in this model family are mechanistically distinct. In envelope-producer lines exemplified by lineage 50-4, non-secreted HBsAg particles accumulate in the endoplasmic reticulum, producing ground-glass hepatocytes and chronic ER stress; hepatocellular injury begins within months, regenerative nodules follow, and adenomas and carcinomas emerge from roughly fifteen months of age onward as proliferation and oxidative DNA damage accumulate. In HBx transgenic mice, first reported by Kim and colleagues in 1991, the viral X protein deregulates host transcription, perturbs p53 function and DNA repair, and activates Wnt/β-catenin and Ras/MAPK signaling — provoking tumors in high-expression lines within a year, with marked male predominance and notably without requiring cirrhosis or chronic inflammation. Because natural history is slow, studies frequently compress timelines with chemical co-carcinogens or hydrodynamic somatic delivery of cooperating oncogenes, positioning the transgenic platform as a versatile backbone for mechanism-driven and therapeutic preclinical research.

Principles of HBV-Transgenic Hepatocellular Carcinoma Model Construction

Constructing this model means aligning three design decisions: which viral gene product to express, how strongly and where to express it, and how to pace tumor emergence. Germline transgenesis places the viral cassette under a hepatocyte-selective promoter — commonly the albumin promoter or the virus's own regulatory elements — yielding uniform, life-long expression without any infection step. Tumor penetrance then tracks expression level and genetic background: envelope-producer lines transform through persistent ER stress and regenerative pressure, whereas HBx lines transform through direct signaling effects. Where faster kinetics or cooperating lesions are required, chemical hepatocarcinogens or hydrodynamic tail-vein co-delivery of oncogenes and tumor-suppressor knockdown constructs can be layered onto either platform.

Our Services

Alfa Cytology provides this service as a complete, auditable package: breeding colonies with genotype confirmation at every generation, scheduled serology and liver imaging, optional acceleration arms designed alongside your team, and terminal histopathological and molecular workups — all executed under documented quality standards so the data you receive withstands scientific scrutiny.

Workflow of HBV-Transgenic Hepatocellular Carcinoma Model Construction

Establishing the HBV-transgenic HCC study is a program of careful animal management punctuated by scheduled analytical checkpoints. The sequence below traces a typical engagement from line selection through final dataset delivery.

1. Study design and platform selection: The research question dictates the backbone: an envelope-producer line for the injury–regeneration paradigm, an HBx line for inflammation-independent oncogenesis, or a wild-type host receiving hydrodynamic HBV-gene delivery — with group sizes, acceleration arms, and endpoint criteria defined up front.
2. Animal sourcing, breeding, and genotype verification: Transgenic breeders are maintained under controlled conditions, litters are genotyped by validated PCR assays, and only confirmed carriers enter the study cohort alongside non-transgenic littermate controls.
3. Baseline characterization: Before any intervention, animals are profiled for body weight, serum transaminases, circulating HBsAg and HBV DNA, and baseline liver histology, ensuring cohorts begin from a documented, comparable state.
4. Optional timeline acceleration: Where compressed kinetics are required, a chemical co-carcinogen challenge or hydrodynamic tail-vein co-delivery of cooperating oncogenes or tumor-suppressor knockdown constructs is applied according to validated SOPs.
5. Longitudinal tumor surveillance: Animals are monitored on schedule for body weight, abdominal distension, and general health, with periodic ultrasound or MRI screening and serum AFP measurement to timestamp tumor emergence non-invasively.
6. Terminal histopathology and immunophenotyping: At endpoint, livers are excised and mapped for lesions; sections are graded by H&E and stained for AFP, glutamine synthetase, and Ki-67 to classify adenoma versus carcinoma and characterize proliferation.
7. Molecular analysis and final reporting: Transgene expression, integration context, and pathway activity are assayed where specified, and all longitudinal and endpoint data are integrated — tumor incidence, latency distributions, and serological kinetics — into the final study report.

Fig 2. HBV-Transgenic Hepatocellular Carcinoma Model Construction Workflow.

Case Study-HBV-Transgenic Hepatocellular Carcinoma Model Development

Alfa Cytology has conducted HBV-transgenic hepatocarcinoma studies for preclinical programs addressing viral oncogenesis mechanisms and candidate anti-HCC agent evaluation. Such programs have typically engaged our genotype-verified transgenic colonies, baseline and interval serological profiling, scheduled imaging surveillance, and terminal histopathological and molecular characterization — producing tumor-incidence, latency, and treatment-response datasets that inform internal development decisions. Representative materials can be shared upon request under appropriate confidentiality arrangements.

Why Choose Alfa Cytology?

Working with germline transgenic liver cancer models demands genetic discipline, patient longitudinal follow-up, and pathology that distinguishes preneoplastic change from true carcinoma. Alfa Cytology builds these capabilities into a single managed workflow, so genotype integrity and histological rigor are never left to chance.

• Genotype-verified transgenic colonies with documented breeding and lineage traceability.
• Choice of envelope-producer, HBx, or hydrodynamic delivery platforms matched to your mechanism of interest.
• Scheduled serology, AFP kinetics, and non-invasive imaging for precise tumor dating.
• Validated acceleration arms, including chemical co-carcinogen and oncogene co-delivery designs.
• Expert histopathological grading with established adenoma-versus-carcinoma marker panels.
• Dedicated preclinical operations with no clinical-service distractions — your research program stays the priority.
• Consolidated reporting that integrates breeding, monitoring, pathology, and molecular data into one auditable package.

Contact Us

To explore how an HBV-transgenic hepatocellular carcinoma platform can advance your liver cancer program, contact us for a consultation, and we will match the right transgenic line and study design to your objectives. Reach out to Alfa Cytology today to receive a customized proposal and projected timeline.

For research use only. Not intended for any clinical use.